Anna E. Vilgelm

3.3k total citations
48 papers, 1.9k citations indexed

About

Anna E. Vilgelm is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Anna E. Vilgelm has authored 48 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 21 papers in Molecular Biology and 17 papers in Immunology. Recurrent topics in Anna E. Vilgelm's work include Cancer-related Molecular Pathways (12 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Anna E. Vilgelm is often cited by papers focused on Cancer-related Molecular Pathways (12 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Anna E. Vilgelm collaborates with scholars based in United States, Russia and Croatia. Anna E. Vilgelm's co-authors include Ann Richmond, Alexander Zaika, Amrendra Kumar, Douglas B. Johnson, Wael El‐Rifai, Sheau‐Chiann Chen, Jinming Yang, Mark C. Kelley, Gregory D. Ayers and Jinxiong Wei and has published in prestigious journals such as Blood, ACS Nano and The Journal of Immunology.

In The Last Decade

Anna E. Vilgelm

44 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna E. Vilgelm United States	23	1.0k	773	630	283	196	48	1.9k
Maarten L. Janmaat Netherlands	17	1.3k 1.2×	1.0k 1.3×	567 0.9×	525 1.9×	156 0.8×	28	2.4k
Venkatesh Krishnan United States	20	758 0.7×	1.1k 1.4×	961 1.5×	242 0.9×	285 1.5×	35	2.3k
Imayavaramban Lakshmanan United States	27	961 0.9×	1.5k 1.9×	504 0.8×	292 1.0×	407 2.1×	43	2.2k
Annemilaï Tijeras‐Raballand France	21	1.2k 1.1×	1.2k 1.5×	540 0.9×	264 0.9×	503 2.6×	47	2.2k
Tomonori Yaguchi Japan	28	989 0.9×	687 0.9×	912 1.4×	281 1.0×	256 1.3×	70	2.0k
Li-Chuan Chan Taiwan	17	1.2k 1.1×	965 1.2×	779 1.2×	425 1.5×	406 2.1×	27	2.1k
Sanaz Memarzadeh United States	23	918 0.9×	1.1k 1.4×	345 0.5×	439 1.6×	424 2.2×	60	2.3k
Xinhui Wang United States	21	917 0.9×	828 1.1×	536 0.9×	251 0.9×	459 2.3×	55	1.9k
Won Jin Ho United States	18	1.3k 1.3×	612 0.8×	629 1.0×	340 1.2×	438 2.2×	59	2.1k
Srinivas Malladi United States	12	952 0.9×	981 1.3×	576 0.9×	211 0.7×	384 2.0×	28	1.9k

Countries citing papers authored by Anna E. Vilgelm

Since Specialization

Citations

This map shows the geographic impact of Anna E. Vilgelm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna E. Vilgelm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna E. Vilgelm more than expected).

Fields of papers citing papers by Anna E. Vilgelm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna E. Vilgelm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna E. Vilgelm. The network helps show where Anna E. Vilgelm may publish in the future.

Co-authorship network of co-authors of Anna E. Vilgelm

This figure shows the co-authorship network connecting the top 25 collaborators of Anna E. Vilgelm. A scholar is included among the top collaborators of Anna E. Vilgelm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna E. Vilgelm. Anna E. Vilgelm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Uthaman, Saji, Darpan N. Pandya, Xiaona Wen, et al.. (2025). Monitoring Response to Combinatorial Immunotherapies by Tracking both T Cells and Natural Killer Cells In Vivo via ImmunoPET-Raman Multimodal Gold Nanostars. ACS Applied Materials & Interfaces. 17(43). 59051–59066.

Bowman, Emily, Amrendra Kumar, Jeffrey C. Horowitz, et al.. (2024). Synergy Between NK Cells and Monocytes in Potentiating Cardiovascular Disease Risk in Severe COVID-19. Arteriosclerosis Thrombosis and Vascular Biology. 44(10). e243–e261. 1 indexed citations

Bharti, Vijaya, N. Roy-Chowdhury, Daniel de Lima Bellan, et al.. (2024). TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING. JCI Insight. 9(15). 5 indexed citations

Yan, Chi, Caroline A. Nebhan, Nabil Saleh, et al.. (2023). Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma. Cancers. 15(14). 3695–3695. 5 indexed citations

Kumar, Amrendra, Vijay Ramani, Vijaya Bharti, et al.. (2023). Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses. Journal for ImmunoTherapy of Cancer. 11(5). e006019–e006019. 10 indexed citations

Bharti, Vijaya, Amrendra Kumar, Rebecca L. Shattuck-Brandt, et al.. (2022). BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Reports. 41(12). 111826–111826. 29 indexed citations

Uzhachenko, Roman V., Vijaya Bharti, Zhufeng Ouyang, et al.. (2021). Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Reports. 35(1). 108944–108944. 61 indexed citations

Yan, Chi, Nabil Saleh, Jinming Yang, et al.. (2021). Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Molecular Cancer. 20(1). 85–85. 28 indexed citations

Bharti, Vijaya, David Westover, Joshua A. Bauer, et al.. (2020). High-throughput drug screening of fine-needle aspiration-derived cancer organoids. STAR Protocols. 1(3). 100212–100212. 13 indexed citations

10.

Scalise, Carly Bess, Caroline A. Nebhan, Jinming Yang, et al.. (2020). Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. Breast Cancer Research and Treatment. 184(2). 357–364. 6 indexed citations

11.

Shattuck-Brandt, Rebecca L., Sheau‐Chiann Chen, Emily Murray, et al.. (2020). Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clinical Cancer Research. 26(14). 3803–3818. 22 indexed citations

12.

Yang, Jinming, Chi Yan, Anna E. Vilgelm, et al.. (2020). Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity. Cancer Immunology Research. 9(2). 200–213. 56 indexed citations

13.

Bechard, Matthew E., Anna E. Vilgelm, Naira Baregamian, et al.. (2020). Obtaining patient-derived cancer organoid cultures via fine-needle aspiration. STAR Protocols. 2(1). 100220–100220. 16 indexed citations

14.

Vilgelm, Anna E., Nabil Saleh, Rebecca L. Shattuck-Brandt, et al.. (2019). MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Science Translational Medicine. 11(505). 88 indexed citations

15.

Ou, Yu‐Chuan, Xiaona Wen, Christopher Andrew Johnson, et al.. (2019). Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. ACS Nano. 14(1). 651–663. 54 indexed citations

16.

Yang, Jinming, Amrendra Kumar, Anna E. Vilgelm, et al.. (2018). Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunology Research. 6(10). 1186–1198. 57 indexed citations

17.

Sai, Jiqing, Philip Owens, Sergey V. Novitskiy, et al.. (2016). PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Clinical Cancer Research. 23(13). 3371–3384. 89 indexed citations

18.

Liu, Yan, Oriana E. Hawkins, Anna E. Vilgelm, et al.. (2015). Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clinical Cancer Research. 21(23). 5338–5348. 20 indexed citations

19.

Vilgelm, Anna E., Jeff S. Pawlikowski, Yan Liu, et al.. (2014). Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. Cancer Research. 75(1). 181–193. 82 indexed citations

20.

Su, Yingjun, Anna E. Vilgelm, Mark C. Kelley, et al.. (2012). RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research. 18(8). 2184–2198. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact